BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 37955537)

  • 1. S100A16 cooperates with DEPDC1 to promote the progression and angiogenesis of nephroblastoma through PI3K/Akt/mTOR pathway.
    Geng G; Xu Y; Li Q; Li Q; Yuan L; Dong M; Ming M
    Pol J Pathol; 2023; 74(3):182-193. PubMed ID: 37955537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FOXO3a‑modulated DEPDC1 promotes malignant progression of nephroblastoma via the Wnt/β‑catenin signaling pathway.
    Geng G; Li Q; Guo X; Ni Q; Xu Y; Ma Z; Wang Y; Ming M
    Mol Med Rep; 2022 Aug; 26(2):. PubMed ID: 35795985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. S100A16 promotes cell proliferation and metastasis via AKT and ERK cell signaling pathways in human prostate cancer.
    Zhu W; Xue Y; Liang C; Zhang R; Zhang Z; Li H; Su D; Liang X; Zhang Y; Huang Q; Liu M; Li L; Li D; Zhao AZ; Liu Y
    Tumour Biol; 2016 Sep; 37(9):12241-12250. PubMed ID: 27240591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transcription factor HOXB2 upregulates NUSAP1 to promote the proliferation, invasion and migration of nephroblastoma cells via the PI3K/Akt signaling pathway.
    Luo B; Feng S; Li T; Wang J; Qi Z; Zhao Y; Hu B
    Mol Med Rep; 2022 Jun; 25(6):. PubMed ID: 35485274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. S100A16 Regulates HeLa Cell through the Phosphatidylinositol 3 Kinase (PI3K)/AKT Signaling Pathway.
    Zhang H; Yang Y; Ma X; Xin W; Fan X
    Med Sci Monit; 2020 Jan; 26():e919757. PubMed ID: 31894756
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Osteopontin promotes tumor growth and metastasis and GPX4-mediated anti-lipid peroxidation in triple-negative breast cancer by activating the PI3k/Akt/mTOR pathway.
    Guo M; Liu M; Li W; Wang C; Zhang L; Zhang H
    J Cancer Res Clin Oncol; 2024 Mar; 150(3):155. PubMed ID: 38526702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ARHGAP9 inhibits colorectal cancer cell proliferation, invasion and EMT via targeting PI3K/AKT/mTOR signaling pathway.
    Sun J; Zhao X; Jiang H; Yang T; Li D; Yang X; Jia A; Ma Y; Qian Z
    Tissue Cell; 2022 Aug; 77():101817. PubMed ID: 35679685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MiR-155-5p exerts tumor-suppressing functions in Wilms tumor by targeting IGF2 via the PI3K signaling pathway.
    Luo X; Dong J; He X; Shen L; Long C; Liu F; Liu X; Lin T; He D; Wei G
    Biomed Pharmacother; 2020 May; 125():109880. PubMed ID: 32004974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Calbindin S100A16 Promotes Renal Cell Carcinoma Progression and Angiogenesis via the VEGF/VEGFR2 Signaling Pathway.
    Wang N; Wang R; Tang J; Gao J; Fang Z; Zhang M; Shen X; Lu L; Chen Y
    Contrast Media Mol Imaging; 2022; 2022():5602011. PubMed ID: 36176934
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ESM1 promotes angiogenesis in colorectal cancer by activating PI3K/Akt/mTOR pathway, thus accelerating tumor progression.
    Yang L; Dong Z; Li S; Chen T
    Aging (Albany NY); 2023 Mar; 15(8):2920-2936. PubMed ID: 37100467
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SPI1 Mediates N-Myristoyltransferase 1 to Advance Gastric Cancer Progression via PI3K/AKT/mTOR Pathway.
    Qiu P; Li X; Gong M; Wen P; Wen J; Xu L; Wang G
    Can J Gastroenterol Hepatol; 2023; 2023():2021515. PubMed ID: 36967718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Scutellarin inhibits the invasive potential of malignant melanoma cells through the suppression epithelial-mesenchymal transition and angiogenesis via the PI3K/Akt/mTOR signaling pathway.
    Li CY; Wang Q; Wang X; Li G; Shen S; Wei X
    Eur J Pharmacol; 2019 Sep; 858():172463. PubMed ID: 31211986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AIM2 inhibits the proliferation, invasion and migration, and promotes the apoptosis of osteosarcoma cells by inactivating the PI3K/AKT/mTOR signaling pathway.
    Zheng J; Liu C; Shi J; Wen K; Wang X
    Mol Med Rep; 2022 Feb; 25(2):. PubMed ID: 34913077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FOXK1 promotes malignant progression of breast cancer by activating PI3K/AKT/mTOR signaling pathway.
    Li ZQ; Qu M; Wan HX; Wang H; Deng Q; Zhang Y
    Eur Rev Med Pharmacol Sci; 2019 Nov; 23(22):9978-9987. PubMed ID: 31799667
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiogenin interacts with ribonuclease inhibitor regulating PI3K/AKT/mTOR signaling pathway in bladder cancer cells.
    Peng Y; Li L; Huang M; Duan C; Zhang L; Chen J
    Cell Signal; 2014 Dec; 26(12):2782-92. PubMed ID: 25193113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long noncoding RNA-JPX predicts the poor prognosis of ovarian cancer patients and promotes tumor cell proliferation, invasion and migration by the PI3K/Akt/mTOR signaling pathway.
    Li J; Feng L; Tian C; Tang YL; Tang Y; Hu FQ
    Eur Rev Med Pharmacol Sci; 2018 Dec; 22(23):8135-8144. PubMed ID: 30556851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of the PI3K/Akt/mTOR/p70S6K pathway is involved in S100A4-induced viability and migration in colorectal cancer cells.
    Wang H; Duan L; Zou Z; Li H; Yuan S; Chen X; Zhang Y; Li X; Sun H; Zha H; Zhang Y; Zhou L
    Int J Med Sci; 2014; 11(8):841-9. PubMed ID: 24936148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LINC00941 promoted in vitro progression and glycolysis of laryngocarcinoma by upregulating PKM via activating the PI3K/AKT/mTOR signaling pathway.
    Li Z; Jin Q; Sun Y
    J Clin Lab Anal; 2022 Jul; 36(7):e24406. PubMed ID: 35588431
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alpha1-ACT Functions as a Tumour Suppressor in Hepatocellular Carcinoma by Inhibiting the PI3K/AKT/mTOR Signalling Pathway via Activation of PTEN.
    Zhu H; Liu Q; Tang J; Xie Y; Xu X; Huang R; Zhang Y; Jin K; Sun B
    Cell Physiol Biochem; 2017; 41(6):2289-2306. PubMed ID: 28456796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FAM83B-mediated activation of PI3K/AKT and MAPK signaling cooperates to promote epithelial cell transformation and resistance to targeted therapies.
    Cipriano R; Miskimen KL; Bryson BL; Foy CR; Bartel CA; Jackson MW
    Oncotarget; 2013 May; 4(5):729-38. PubMed ID: 23676467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.